^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Thymic Carcinoma

    Related cancers:
    Apply
    Safety and Efficacy of CD70-Targeted CAR-T Therapy in CD70-Positive Advanced Solid Tumors: A Clinical Trial (NCT07181720)
    Phase 1
    Chongqing Precision Biotech Co., Ltd
    Recruiting
    Last update posted :
    09/18/2025
    Initiation :
    09/12/2025
    Primary completion :
    03/31/2028
    Completion :
    05/31/2028
    CD70
    |
    cyclophosphamide • fludarabine IV • CD70 CAR-T
    A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers (NCT05544929)
    Phase 1
    Novartis Pharmaceuticals
    Recruiting
    Last update posted :
    02/06/2025
    Initiation :
    10/26/2022
    Primary completion :
    02/20/2026
    Completion :
    02/20/2026
    MSI
    |
    MSI-H/dMMR
    |
    Keytruda (pembrolizumab) • Tevimbra (tislelizumab-jsgr) • KFA115
    A Pilot Study to Investigate the Safety and Clinical Activity of Avelumab (MSB0010718C) in Thymoma and Thymic Carcinoma After Progression on Platinum-Based Chemotherapy (NCT03076554)
    Phase 2
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    02/04/2025
    Initiation :
    04/19/2017
    Primary completion :
    06/30/2025
    Completion :
    06/30/2026
    PD-L1
    |
    Bavencio (avelumab)
    Phase I/II Eval Safety & Prelim Activity Nivolumab Comb W/Vorolanib Pts W/Refractory Thoracic Tumors (CA209-982) (NCT03583086)
    Phase 1/2
    Vanderbilt-Ingram Cancer Center
    Completed
    Last update posted :
    10/08/2024
    Initiation :
    07/10/2018
    Primary completion :
    02/21/2024
    Completion :
    04/27/2024
    EGFR • PD-L1 • BRAF • ROS1
    |
    Opdivo (nivolumab) • Fumena (vorolanib)
    Combination of Pembrolizumab and Lenvatinib, in Pre-treated Thymic CArcinoma paTIents (PECATI) (NCT04710628)
    Phase 2
    MedSIR
    Active, not recruiting
    Last update posted :
    08/08/2024
    Initiation :
    09/21/2021
    Primary completion :
    07/01/2024
    Completion :
    01/31/2026
    PD-L1
    |
    PD-L1 expression
    |
    Keytruda (pembrolizumab) • Lenvima (lenvatinib)
    Selective TrkA Inhibitor VMD-928 to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma (NCT03556228)
    Phase 1
    VM Oncology, LLC
    Recruiting
    Last update posted :
    05/31/2024
    Initiation :
    06/08/2018
    Primary completion :
    12/01/2025
    Completion :
    06/01/2026
    NTRK1
    |
    NTRK1 fusion • NTRK1 mutation • NTRK expression
    |
    VMD-928
    Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies (NCT01306045)
    Phase 2
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    04/09/2024
    Initiation :
    02/08/2011
    Primary completion :
    02/12/2014
    Completion :
    12/31/2024
    EGFR • BRAF
    |
    EGFR mutation
    |
    erlotinib • sunitinib • lapatinib • Koselugo (selumetinib) • MK-2206
    Abexinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumor Malignancies (NCT03590054)
    Phase 1
    Rahul Aggarwal
    Completed
    Last update posted :
    03/22/2024
    Initiation :
    08/20/2018
    Primary completion :
    11/30/2023
    Completion :
    11/30/2023
    MSI
    |
    MSI-H/dMMR
    |
    Keytruda (pembrolizumab) • abexinostat (CG-781)
    Pembrolizumab and Sunitinib Malate in Treating Participants With Refractory Metastatic or Unresectable Thymic Cancer (NCI-2018-00192) (NCT03463460)
    Phase 2
    Dwight Owen
    Suspended
    Last update posted :
    03/15/2024
    Initiation :
    06/19/2018
    Primary completion :
    12/31/2024
    Completion :
    12/31/2025
    PD-L1
    |
    PD-L1 expression
    |
    Keytruda (pembrolizumab) • sunitinib
    First-line CBDCA/PTX/LEN/Pembrolizumab Combination for Previously Untreated Advanced or Recurrent Thymic Carcinomas (Artemis) (NCT05832827)
    Phase 2
    National Cancer Center, Japan
    Recruiting
    Last update posted :
    10/20/2023
    Initiation :
    09/04/2023
    Primary completion :
    12/31/2025
    Completion :
    06/30/2028
    KIT • CD5 • TP63
    |
    CD5 positive
    |
    Keytruda (pembrolizumab) • carboplatin • paclitaxel • Lenvima (lenvatinib)
    Molecular Analysis of Thoracic Malignancies (NCT01385722)
    Phase N/A
    Stanford University
    Enrolling by invitation
    Last update posted :
    07/19/2023
    Initiation :
    08/01/2011
    Primary completion :
    06/01/2031
    Completion :
    06/01/2031
    BRAF
    Nivolumab in Patients With Type B3 Thymoma and Thymic Carcinoma (NIVOTHYM) (NCT03134118)
    Phase 2
    European Organisation for Research and Treatmen...
    Active, not recruiting
    Last update posted :
    02/21/2023
    Initiation :
    04/11/2018
    Primary completion :
    12/01/2023
    Completion :
    07/01/2024
    PD-L1
    |
    PD-L1 expression
    |
    Opdivo (nivolumab)